Home Cart Sign in  
Chemical Structure| 5370-01-4 Chemical Structure| 5370-01-4

Structure of Mexiletine HCl
CAS No.: 5370-01-4

Chemical Structure| 5370-01-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Mexiletine HCl is a non-selective blocker of voltage-gated sodium channel. It blongs to the anti-arrhythmic compounds of class IB .

Synonyms: KOE-1173 hydrochloride; Mexiletine(hydrochloride); Ko 1173

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Mexiletine HCl

CAS No. :5370-01-4
Formula : C11H18ClNO
M.W : 215.72
SMILES Code : CC(N)COC1=C(C)C=CC=C1C.[H]Cl
Synonyms :
KOE-1173 hydrochloride; Mexiletine(hydrochloride); Ko 1173
MDL No. :MFCD00216024
InChI Key :NFEIBWMZVIVJLQ-UHFFFAOYSA-N
Pubchem ID :21467

Safety of Mexiletine HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Mexiletine is an orally effective antiarrhythmic agent noted for its benefits in treating myotonia and neuropathic pain. It operates by inhibiting sodium channels, with an IC50 of 75±8 μM for tonic block and 23.6±2.8 μM for use-dependent block, making it relevant for both cardiovascular and neurological research[1].[2].[3].[4].[5].
Target
  • Sodium Channel

In Vitro:

Cell Line
Concentration Treated Time Description References
Casq2−/− myocytes 100 μM 10 min Mexiletine had no significant effects on Ca2+ wave parameters at the highest concentration tested (100 μM) J Mol Cell Cardiol. 2011 Nov;51(5):760-8
Mouse cardiomyocytes 100–1,000 µM 3 minutes Evaluate the inhibitory effect of JME-173 on L-type Ca++ currents, finding it was 12-fold more potent than Mexiletine Front Pharmacol. 2020 Jul 30;11:1159
GH3 cells 0.28 mM Evaluate the blocking effect of JME-173 on Na+ channels, finding its potency to block Na+ currents was 653-fold lower than Mexiletine Front Pharmacol. 2020 Jul 30;11:1159
Casq2−/− cardiomyocytes 6 μmol/L 30 minutes Mexiletine had no significant effect on isoproterenol-induced spontaneous Ca2+ waves Circ Arrhythm Electrophysiol. 2011 Apr;4(2):128-35
ClCadr muscle fibers 10, 25, 50, 100 μM To evaluate the effect of Mexiletine on the excitability of ClCadr muscle fibers. At 10 and 25 μM, most fibers remained hyperexcitable; at 50 μM, there was a wide range in excitability; and at 100 μM, almost all fibers were hypoexcitable. Ann Neurol. 2015 Feb;77(2):320-32
ADR mouse skeletal muscle fibers 30 μM 30 minutes To evaluate the antimyotonic effects of Mexiletine on sarcolemma excitability in ADR mouse skeletal muscle fibers. Mexiletine at 30 μM reduced the number of action potentials, with effects comparable to 10 μM sa finamide. Neurotherapeutics. 2024 Oct;21(6):e00455
ADR mouse skeletal muscle fibers 10 μM 30 minutes To evaluate the antimyotonic effects of Mexiletine on sarcolemma excitability in ADR mouse skeletal muscle fibers. Mexiletine at 10 μM reduced the number of action potentials by 24.4%. Neurotherapeutics. 2024 Oct;21(6):e00455
Rat tracheal rings 10–100 µM 15 minutes Assess the inhibitory effect of JME-173 on carbachol-induced tracheal contraction, finding JME-173 was 15-fold more potent than Mexiletine Front Pharmacol. 2020 Jul 30;11:1159

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice Cisplatin or oxaliplatin-induced neuropathy model Intraperitoneal injection 10 mg/kg Single dose, assessed 1 hour after administration To evaluate the analgesic effects of mexiletine on cisplatin or oxaliplatin-induced neuropathy, results showed mexiletine was ineffective in both models Neuro Oncol. 2014 Oct;16(10):1324-32
Mice TGM(NS31)L12 transgenic mice Intraperitoneal injection 25 mg/kg Twice daily for 14 days To evaluate the effect of mexiletine on arrhythmias, results showed that mexiletine significantly suppressed spontaneous VT/VF in transgenic mice Cardiovasc Res. 2004 Feb 1;61(2):256-67
Mice Mouse model of myotonia congenita Intraperitoneal injection 5, 10, 20, 40 mg/kg Single injection, effects evaluated at 5 to 15 minutes To evaluate the effect of Mexiletine on motor function in a mouse model of myotonia congenita. Mexiletine at 20 mg/kg significantly improved motor function, but at 40 mg/kg, mild ataxia was observed. Ann Neurol. 2015 Feb;77(2):320-32
ADR mice Myotonia model Intraperitoneal injection 10 mg/kg Single administration, effects measured over 120 minutes To evaluate the in vivo antimyotonic effects of Mexiletine in ADR mice. Mexiletine at 10 mg/kg significantly reduced TRR, but was less potent than sa finamide. Neurotherapeutics. 2024 Oct;21(6):e00455
Mice AMPA-induced lethality model Subcutaneous injection 24.5 – 81.5 mg/kg s.c. Single dose Mexiletine partially protected mice against AMPA-induced lethality with a maximum effect of 30-60%. Br J Pharmacol. 2001 Jul;133(6):789-96
Mice Trpm4 knockout mice Langendorff perfusion 40 µg/mL Single dose, 20 minutes duration To study the effect of Mexiletine on cardiac electrical activity in Trpm4?/? mice, results showed that Trpm4?/? hearts were more sensitive to Mexiletine with more pronounced QRS broadening. Int J Mol Sci. 2021 Mar 26;22(7):3401

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02308748 Drug-induced QT Prolongation ... More >> Pharmacokinetics Pharmacodynamics Less << Phase 1 Completed - -
NCT02336477 Non-dystrophic Myotonias ... More >> Paramyotonia Congenita Myotonia Congenita Less << Phase 3 Completed - France ... More >> Groupe Hospitalier Pitié Salpetriere Paris, France, 75013 Less <<
NCT02045667 Non Dystrophic Myotonia Phase 2 Completed - Netherlands ... More >> Departments of Neurology, Radboud University Nijmegen Medical Centre, the Netherlands Nijmegen, Gelderland, Netherlands, 6500HB Less <<
NCT02308748 - Completed - -
NCT01849770 Sporadic Amyotrophic Lateral S... More >>clerosis Less << Phase 2 Completed - United States, California ... More >> UCLA, Neuromuscular Research Center Los Angeles, California, United States, 90095 United States, Iowa University of Iowa Iowa City, Iowa, United States, 52242 United States, Kansas University of Kansas Medical Center Kansas City, Kansas, United States, 66160 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 University of Massachusetts (Worcester) Memorial Medical Center Worcester, Massachusetts, United States, 01655 United States, Missouri Washington University Medical School Saint Louis, Missouri, United States, 63110 United States, New York SUNY Upstate Medical Center Syracuse, New York, United States, 13210 United States, Pennsylvania Penn State Hershey Medical Center Hershey, Pennsylvania, United States, 17033 United States, Texas University of Texas Southwestern Medical Center at Dallas Dallas, Texas, United States, 75390-8897 United States, Washington University of Washington Medical Center Seattle, Washington, United States, 98195 Less <<
NCT02114528 Ventricular Tachycardia ... More >> Ventricular Arrhythmia Less << Phase 4 Terminated(Low recruitment. Pi... More >>lot trial.) Less << - Canada, Ontario ... More >> University of Ottawa Heart Institute Ottawa, Ontario, Canada, K1Y 4W7 Less <<
NCT01849770 - Completed - -
NCT01406873 Myotonic Dystrophy Phase 2 Completed - United States, New York ... More >> University of Rochester Medical Center, Department of Neurology Rochester, New York, United States, 14642 Less <<
NCT01406873 - Completed - -
NCT02781454 Sporadic Amyotrophic Lateral S... More >>clerosis Less << Phase 2 Active, not recruiting December 31, 2018 United States, Arizona ... More >> Barrow Neurological Institute Phoenix, Arizona, United States, 85013 United States, California University of California, Irvine Orange, California, United States, 92868 United States, Georgia Augusta University Augusta, Georgia, United States, 30912 United States, Massachusetts Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, New York Columbia Universtiy Medical Center New York, New York, United States, 10032 United States, Pennsylvania Pennsylvania State Hershey Medical Center Hershey, Pennsylvania, United States, 17033 University of Pittsburgh Pittsburgh, Pennsylvania, United States, 15213 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 United States, Washington University of Washington Seattle, Washington, United States, 98195 Less <<
NCT00000793 HIV Infections ... More >> Peripheral Nervous System Disease Less << Phase 2 Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.64mL

0.93mL

0.46mL

23.18mL

4.64mL

2.32mL

46.36mL

9.27mL

4.64mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records

Categories